NCT03369886

Brief Summary

Macular GCIPLT and vessel density will be measured with Spectralis optical coherence tomography and Topcon swept-source OCT respectively. Linear, quadratic and exponential regression models will be used to investigate relationship between GCIPLT and vessel density. Multilayer neural network will bel used to make single combined parameter and the diagnostic performance will be also compared.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
206

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2017

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 25, 2017

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 6, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 12, 2017

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2018

Completed
Last Updated

December 29, 2017

Status Verified

December 1, 2017

Enrollment Period

11 months

First QC Date

December 6, 2017

Last Update Submit

December 28, 2017

Conditions

Keywords

OCTAAngiographyArtificial neural network

Outcome Measures

Primary Outcomes (1)

  • Vessel density

    Macular vessel density measured by optical coherence tomography angiography

    20 minutes

Study Arms (2)

Early glaucoma group

OTHER

Patients whose visual field mean deviation is \> -6dB OCT angiography will be taken but there are no difference between patients' group. The same OCT angiography protocol will be applied to all patients' group.

Diagnostic Test: Optical Coherence Tomography Angiography (OCTA)

Advanced glaucoma group

OTHER

Patients whose visual field mean deviation is \< -6dB OCT angiography will be taken but there are no difference between patients' group. The same OCT angiography protocol will be applied to all patients' group.

Diagnostic Test: Optical Coherence Tomography Angiography (OCTA)

Interventions

The images will be obtained using a commercial swept-source OCT (SS-OCT) device (DRI OCT Atlantis; Topcon, Tokyo, Japan). SS-OCT uses infrared light, wavelength of 1050 nm which is longer than conventional SD-OCT, at 100,000 A-scans per second. This longer infrared light source has advantages of deep signal penetration through the retina and choroid. Its axial and transversal resolution is 7 and 20 μm in tissue, respectively. Volumetric OCT scans were taken from 6 × 6 mm cubes. Each cube consists of 320 clusters of 4 repeated B-scans centered on the fovea. Moving objects (mostly blood flows) are detected by measuring intensity fluctuations from these repeatedly scanned OCT images. Automated segmentation was performed by OCT software to separate each layer of the retina. The en-face images of the superficial capillary network were derived from an en-face slab, ranged from the internal limiting membrane (ILM) to the inner border of the inner nuclear layer (INL).

Advanced glaucoma groupEarly glaucoma group

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • participants were age \> 18 years
  • clear cornea and clear ocular media
  • BCVA ≥ 20/40
  • a refractive error within ± 6.0 diopters (D), and astigmatism ± 3.0 D.

You may not qualify if:

  • History of diabetes, uveitis, secondary glaucoma
  • corneal abnormalities, non-glaucomatous optic neuropathies
  • Previous ocular trauma
  • Previous ocular surgery or laser treatment,
  • Any other eye disease except for glaucoma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pusan National University Hospital

Busan, 49214, South Korea

RECRUITING

Related Publications (3)

  • Leveque PM, Zeboulon P, Brasnu E, Baudouin C, Labbe A. Optic Disc Vascularization in Glaucoma: Value of Spectral-Domain Optical Coherence Tomography Angiography. J Ophthalmol. 2016;2016:6956717. doi: 10.1155/2016/6956717. Epub 2016 Feb 22.

  • Rao HL, Pradhan ZS, Weinreb RN, Riyazuddin M, Dasari S, Venugopal JP, Puttaiah NK, Rao DA, Devi S, Mansouri K, Webers CA. A comparison of the diagnostic ability of vessel density and structural measurements of optical coherence tomography in primary open angle glaucoma. PLoS One. 2017 Mar 13;12(3):e0173930. doi: 10.1371/journal.pone.0173930. eCollection 2017.

  • Suh MH, Zangwill LM, Manalastas PI, Belghith A, Yarmohammadi A, Medeiros FA, Diniz-Filho A, Saunders LJ, Weinreb RN. Deep Retinal Layer Microvasculature Dropout Detected by the Optical Coherence Tomography Angiography in Glaucoma. Ophthalmology. 2016 Dec;123(12):2509-2518. doi: 10.1016/j.ophtha.2016.09.002. Epub 2016 Oct 18.

MeSH Terms

Conditions

Glaucoma, Open-Angle

Condition Hierarchy (Ancestors)

GlaucomaOcular HypertensionEye Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Model Details: 3 subject groups: 1. Normal control: Subjects who has normal fundus, normal visual field and normal intraocular pressure. 2. Early glaucoma: : Patients who shows glaucomatous visual field abnormality but visual field mean deviation is \> -6 dB 3. Advanced glaucoma : Patients who shows glaucomatous visual field abnormality but visual field mean deviation is \< -6 dB
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 6, 2017

First Posted

December 12, 2017

Study Start

September 25, 2017

Primary Completion

August 31, 2018

Study Completion

August 31, 2018

Last Updated

December 29, 2017

Record last verified: 2017-12

Data Sharing

IPD Sharing
Will share

Unpersonalized measurement data and ophthalmic examination data can be shared with other researchers.

Shared Documents
STUDY PROTOCOL, SAP, ANALYTIC CODE
Time Frame
Sharing will be started from 31 August 2018 (anticipated) for 2 years.
Access Criteria
Data will be shared on request (contact email: climyth@naver.com)

Locations